45 related articles for article (PubMed ID: 33442658)
1. Worse histopathology and prognosis in women with breast cancer diagnosed during the second trimester of pregnancy.
Gkekos L; Lundberg FE; Humphreys K; Fredriksson I; Johansson ALV
ESMO Open; 2024 Apr; 9(4):102972. PubMed ID: 38520846
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of cause of death data routinely recorded in a population-based cancer registry: impact on cause-specific survival and validation using the Geneva Cancer Registry.
Schaffar R; Rapiti E; Rachet B; Woods L
BMC Cancer; 2013 Dec; 13():609. PubMed ID: 24373194
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm.
Yan S; Wang Y; Guo Y; Zhang Y; Peng H; Tang H; Luo Y; Zhang A; Gao H
Oncol Lett; 2023 Nov; 26(5):491. PubMed ID: 37854866
[TBL] [Abstract][Full Text] [Related]
4. Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy.
Sopik V; Lim D; Sun P; Narod SA
Curr Oncol; 2023 Mar; 30(4):3829-3844. PubMed ID: 37185403
[TBL] [Abstract][Full Text] [Related]
5. Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.
Rask G; Nazemroaya A; Jansson M; Wadsten C; Nilsson G; Blomqvist C; Holmberg L; Wärnberg F; Sund M
Breast Cancer Res Treat; 2022 Oct; 195(3):367-377. PubMed ID: 35933487
[TBL] [Abstract][Full Text] [Related]
6.
Jaraj D; Höijer J; Widman L; Ahlgren J; Arnesson LG; Einbeigi Z; Klintman M; Vikhe Patil E; Sund M; Fredriksson I; Bergh J; Andreas P
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442658
[TBL] [Abstract][Full Text] [Related]
7. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
8. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
9. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
10. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
11. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of pT1a-b, cN0 breast cancer without axillary dissection or staging: a prospective observational study of 1543 women.
Ingvar C; Ahlgren J; Emdin S; Lofgren L; Nordander M; Niméus E; Arnesson LG
Br J Surg; 2020 Sep; 107(10):1299-1306. PubMed ID: 32335901
[TBL] [Abstract][Full Text] [Related]
13. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2019 Apr; 393(10179):1440-1452. PubMed ID: 30739743
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
